MedTrace Logo

Effects of a Long-term Grapefruit Juice Consumption on Vascular Protection and Bone Metabolism

NCT01272167 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2014-07-08

No results posted yet for this study

Summary

Epidemiological studies definitively show that fruit and vegetable consumption is an important factor for the prevention of age-related diseases such as cardiovascular diseases (CVD) and osteoporosis. Citrus fruits are among the fruits which are the most frequently consumed worldwide, essentially as juices.

Citrus fruits are the exclusive sources of a particular class of dietary flavonoids, namely flavanones. Grapefruit consumed as whole fruit or juice corresponds to a quantitatively significant source of a specific flavanone called naringin.

Conditions

  • Post-menopausal Status

Interventions

BEHAVIORAL

Long-term grapefruit juice consumption

The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.

Sponsors & Collaborators

  • INRA de Clermont-Fd / Theix

    collaborator UNKNOWN

  • UMR 1019 Unité de Nutrition Humaine

    collaborator UNKNOWN

  • Equipe MiMes

    collaborator UNKNOWN

  • 63122 Saint-Genès Champanelle

    collaborator UNKNOWN

  • FRANCE

    collaborator UNKNOWN

  • University Hospital, Clermont-Ferrand

    lead OTHER

Principal Investigators

  • Claude DUBRAY · University Hospital, Clermont-Ferrand

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01272167 on ClinicalTrials.gov